Advertisement

Advertisement
Multiple Myeloma
Immunotherapy

FDA Grants Accelerated Approval to Belantamab Mafodotin-blmf for Pretreated Patients With Relapsed or Refractory Multiple Myeloma

On August 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to belantamab mafodotin-blmf (Blenrep)...

Lymphoma
Immunotherapy

Anti-CD30 CAR T-Cell Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma

In a pooled analysis of two parallel single-center phase I/II studies reported in the Journal of Clinical Oncology, Ramos et al found that...

Pancreatic Cancer

Addition of Pegvorhyaluronidase Alfa to Nab-paclitaxel and Gemcitabine in Hyaluronan-High Metastatic Pancreatic Cancer

In the phase III HALO 109-301 trial reported in the Journal of Clinical OncologyEric Van Cutsem, MD, PhD, and colleagues found that the addition...


Advertisement
Hepatobiliary Cancer
Immunotherapy

Combination Immunotherapy in Advanced Biliary Tract Cancers

In a subgroup analysis of an Australian phase II trial reported in JAMA Oncology, Klein et al found that the combination of nivolumab and ipilimumab...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Multiple Myeloma

Shaji Kumar, MD, on Multiple Myeloma: Phase III Results on Carfilzomib, Lenalidomide, Bortezomib, and Dexamethasone

Pancreatic Cancer

Addition of Pegvorhyaluronidase Alfa to Nab-paclitaxel and Gemcitabine in Hyaluronan-High Metastatic Pancreatic Cancer

In the phase III HALO 109-301 trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the addition of pegvorhyaluronidase alfa (PEGPH20) to nab-paclitaxel plus gemcitabine (AG) did not improve overall survival or progression-free survival in patients...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Prostate Cancer

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy

Hepatobiliary Cancer
Immunotherapy

First-Line Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

In a phase Ib trial reported in the Journal of Clinical Oncology, Richard S. Finn, MD, and colleagues found that the combination of lenvatinib and pembrolizumab produced durable responses in patients with unresectable hepatocellular carcinoma who had received no prior systemic chemotherapy. As...

COVID-19
Breast Cancer
Colorectal Cancer
Gastroesophageal Cancer
Lung Cancer

Modeling Study Aims to Estimate the Effect of the COVID-19 Pandemic on Cancer Deaths in England

In a population-based modeling study reported in The Lancet Oncology, Maringe et al estimated that delays in diagnosis due to the COVID-19 pandemic could result in 3,291 to 3,621 additional deaths from breast, colorectal, esophageal, and lung cancers within 5 years. As stated by the investigators, ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Prostate Cancer

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy

Prostate Cancer

Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer

A new multi-institution, dose-determining clinical trial of a compound for patients with metastatic, castration-resistant prostate cancer showed the combination “demonstrated acceptable tolerability and potential efficacy,” reported Aggarwal et al in Clinical Cancer Research. The phase Ib/IIa study ...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...